Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 6/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 4/20 | 0.36 |
| ▸ | STAT6 | P42226 | 3/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19666503 | 0.86 | MEN1 (0.46) | EGFRITKAURKASTAT6PTK2 | |
| SCHEMBL19666586 | 0.85 | STAT6 (0.41) | MAPK8EGFRITKAURKASYK | |
| SCHEMBL19666334 | 0.81 | IGF1R (0.46) | MAPK8SYKSTAT6 | |
| SCHEMBL19666633 | 0.73 | MAPK8 (0.41) | MAPK8SYK | |
| SCHEMBL19666624 | 0.71 | MEN1 (0.49) | EGFRAURKASTAT6PTK2 | |
| SCHEMBL19666509 | 0.69 | MEN1 (0.44) | AURKASYKSTAT6PTK2 | |
| SCHEMBL19666435 | 0.68 | MAPK8 (0.45) | MAPK8SYK | |
| SCHEMBL1934601 | 0.67 | SCN9A (0.49) | MAPK8EGFRITKAURKA | |
| SCHEMBL29717589 | 0.67 | MAPK8 (0.43) | MAPK8SYK | |
| SCHEMBL19666269 | 0.67 | MAPK8 (0.43) | MAPK8SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3464312-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | disclosed |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| WO-2017210408-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | MAPK8 1870/4885EGFR 4879/4885ITK 4153/4885 |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | MAPK8 1870/4885EGFR 4879/4885ITK 4153/4885 |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | MAPK8 1870/4885EGFR 4879/4885ITK 4153/4885 |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | MAPK8 1870/4885EGFR 4879/4885ITK 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.